Brenda K. Mann, PhD, is Vice President for Research and Development at EyeGate Pharmaceuticals, focusing on ocular drug delivery, as well as adjunct faculty in the Department of Bioengineering at the University of Utah. She holds a BS and PhD in chemical engineering from Iowa State University
and Rice University, respectively.
Prior to joining EyeGate, Dr. Mann was a Co-Founder and Vice President for Research & Development at SentrX Animal Care, focused on veterinary biomaterials, where she developed four product lines marketed and sold worldwide. She was also a founding faculty member of Keck Graduate Institute and is a registered patent agent.
Mann’s current research focuses on developing innovative ocular drug delivery methods, including polymeric and iontophoretic means. She has extensive experience with developing biomaterials for tissue engineering, wound healing, and drug delivery applications; stereolithography of tissue engineering scaffolds; and 3D models for high-throughput drug screening.
Mann received the Rice University Outstanding Woman Award in 1996, the Young Investigator Award from the International Society for Applied Cardiovascular Biology in 2000, the Teacher Tribute Award from Stanford University in 2015, and was a Utah Women Tech Award finalist in 2008 and 2016. She is a strong proponent of youth science education and has served as the Director of the University of Utah Science and Engineering Fair since 2006.